A. Visvikis

541 total citations
18 papers, 398 citations indexed

About

A. Visvikis is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, A. Visvikis has authored 18 papers receiving a total of 398 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 5 papers in Surgery and 5 papers in Oncology. Recurrent topics in A. Visvikis's work include Bladder and Urothelial Cancer Treatments (4 papers), Urinary and Genital Oncology Studies (4 papers) and Lung Cancer Treatments and Mutations (4 papers). A. Visvikis is often cited by papers focused on Bladder and Urothelial Cancer Treatments (4 papers), Urinary and Genital Oncology Studies (4 papers) and Lung Cancer Treatments and Mutations (4 papers). A. Visvikis collaborates with scholars based in Greece, Cyprus and United Kingdom. A. Visvikis's co-authors include Eleni Galani, G. Klouvas, C. Christodoulou, Georgios T. Karapanagiotidis, Matthew E. Falagas, Dimosthenis Skarlos, D. Pectasides, A. Athanassiou, George Fountzilas and Dimitrios Pectasides and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

A. Visvikis

18 papers receiving 380 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Visvikis Greece 9 261 122 119 104 52 18 398
Julius Moratin Germany 14 232 0.9× 168 1.4× 104 0.9× 59 0.6× 94 1.8× 56 514
Payam Entezami United States 9 136 0.5× 58 0.5× 50 0.4× 75 0.7× 131 2.5× 20 389
Michèle Magremanne Belgium 11 196 0.8× 40 0.3× 80 0.7× 127 1.2× 26 0.5× 35 312
Yasmin Rahim Canada 9 439 1.7× 115 0.9× 165 1.4× 76 0.7× 111 2.1× 17 542
George C. Bohle United States 9 391 1.5× 91 0.7× 123 1.0× 269 2.6× 16 0.3× 13 538
William Hage United States 6 118 0.5× 210 1.7× 78 0.7× 45 0.4× 22 0.4× 10 327
Peter Zbaeren Switzerland 7 158 0.6× 250 2.0× 41 0.3× 23 0.2× 31 0.6× 8 403
Primo Andrea Daolio Italy 12 93 0.4× 121 1.0× 233 2.0× 46 0.4× 42 0.8× 25 410
Mika Sampo Finland 14 178 0.7× 128 1.0× 305 2.6× 29 0.3× 63 1.2× 35 461
Roberto Bruschini Italy 16 288 1.1× 447 3.7× 137 1.2× 40 0.4× 20 0.4× 39 729

Countries citing papers authored by A. Visvikis

Since Specialization
Citations

This map shows the geographic impact of A. Visvikis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Visvikis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Visvikis more than expected).

Fields of papers citing papers by A. Visvikis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Visvikis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Visvikis. The network helps show where A. Visvikis may publish in the future.

Co-authorship network of co-authors of A. Visvikis

This figure shows the co-authorship network connecting the top 25 collaborators of A. Visvikis. A scholar is included among the top collaborators of A. Visvikis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Visvikis. A. Visvikis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Liontos, Michalis, Anna Goussia, Nikolaos Korfiatis, et al.. (2024). The role of Cabazitaxel in Patients With Castration-Resistant and Osseous Metastases Prostate Cancer. A Hellenic Cooperative Oncology Group Phase II Study. Clinical Genitourinary Cancer. 23(1). 102253–102253. 1 indexed citations
2.
Papadopoulou, Kyriaki, Georgia-Angeliki Koliou, Vassiliki Kotoula, et al.. (2022). Investigation of prognostic biomarkers in patients with urothelial carcinoma treated with platinum-based regimens. Urologic Oncology Seminars and Original Investigations. 40(12). 538.e15–538.e24. 1 indexed citations
3.
Dimitrakopoulos, Foteinos‐Ioannis, Georgia-Angeliki Koliou, Vassiliki Kotoula, et al.. (2021). Genetic Variation in the Vascular Endothelial Growth Factor (VEGFA) Gene at rs13207351 Is Associated with Overall Survival of Patients with Head and Neck Cancer. Cancers. 13(5). 1163–1163. 4 indexed citations
4.
Fountzilas, Elena, Vassiliki Kotoula, Georgia-Angeliki Koliou, et al.. (2021). Tumor Genotyping and Homologous Recombination Repair Gene Variants in Patients With Epithelial Ovarian Cancer: Is Pathogenic Enough?. Frontiers in Oncology. 11. 683057–683057. 1 indexed citations
5.
Koliou, Georgia-Angeliki, Foteinos‐Ioannis Dimitrakopoulos, Kyriaki Papadopoulou, et al.. (2020). Genetic Variations of VEGFA Gene Are Associated With Infiltration of Adjacent Tissues and the Clinical Outcome of Patients With Nasopharyngeal Carcinoma. Anticancer Research. 40(2). 677–688. 4 indexed citations
6.
Visvikis, A., Christos Georgakopoulos, Kyriaki Manousou, et al.. (2020). <p>Cardiotoxic Profile and Arterial Stiffness of Adjuvant Chemotherapy for Colorectal Cancer</p>. Cancer Management and Research. Volume 12. 1175–1185. 5 indexed citations
7.
8.
9.
Christodoulou, C., G. Klouvas, Eleni Galani, et al.. (2009). Combination of Bisphosphonates and Antiangiogenic Factors Induces Osteonecrosis of the Jaw More Frequently than Bisphosphonates Alone. Oncology. 76(3). 209–211. 177 indexed citations
10.
Pectasides, Dimitrios, et al.. (2009). Successful management of extracranial metastases from cerebral high-grade oligodendroglioma: report of a case with literature review.. PubMed. 7(3). 273–6. 1 indexed citations
11.
Pectasides, D., et al.. (2002). Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer. European Journal of Cancer. 38(9). 1194–1200. 13 indexed citations
12.
Pectasides, D., Haralabos P. Kalofonos, Epaminontas Samantas, et al.. (2001). An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.. PubMed. 21(4B). 3005–10. 17 indexed citations
13.
Pectasides, D., Gerasimos Aravantinos, Haralabos P. Kalofonos, et al.. (2001). Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology. 12(10). 1417–1422. 28 indexed citations
14.
Pectasides, Dimitrios, et al.. (2000). Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial. European Journal of Cancer. 36(1). 74–79. 22 indexed citations
15.
Visvikis, A., et al.. (1999). Squamous Cell Carcinoma Antigen, Circulating Immune Complexes, and Immunoglobulins in Monitoring Squamous Cell Carcinoma of Head and Neck. American Journal of Clinical Oncology. 22(6). 542–542. 6 indexed citations
16.
Pectasides, D., Gerasimos Aravantinos, A. Visvikis, et al.. (1999). Platinum-Based Chemotherapy of Primary Extragonadal Germ Cell Tumours: The Hellenic Cooperative Oncology Group Experience. Oncology. 57(1). 1–9. 9 indexed citations
17.
Pectasides, D., et al.. (1999). Combination Chemotherapy With Carboplatin, Docetaxel, and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: A Phase II Study. Journal of Clinical Oncology. 17(12). 3816–3821. 23 indexed citations
18.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julius Moratin Breakdown of academic impact, for papers by Payam Entezami Breakdown of academic impact, for papers by Michèle Magremanne Breakdown of academic impact, for papers by Yasmin Rahim Breakdown of academic impact, for papers by George C. Bohle Breakdown of academic impact, for papers by William Hage Breakdown of academic impact, for papers by Peter Zbaeren Breakdown of academic impact, for papers by Primo Andrea Daolio Breakdown of academic impact, for papers by Mika Sampo Breakdown of academic impact, for papers by Roberto Bruschini
Rankless by CCL
2026